Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Wave Life Sciences (WVE)
NASDAQ:WVE
Holding WVE?
Track your performance easily
WVE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.50 - $7.67
Previous Close$5.62
Volume634.93K
Average Volume (3M)868.78K
Market Cap
$688.31M
Enterprise Value$537.94M
Total Cash (Recent Filing)$180.90M
Total Debt (Recent Filing)$30.53M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Aug 01, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding122,460,160
10 Day Avg. Volume553,215
30 Day Avg. Volume868,782
Standard Deviation0.29
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)25.00
Price to Sales (P/S)22.13
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.76
Enterprise Value/Gross Profit4.75
Enterprise Value/Ebitda-8.64
Forecast
1Y Price Target
$13.83Price Target Upside130.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Wave Life Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsWave announced the biomarker and functional data from the Phase 1b/2a SELECT-HD clinical trial, showing for the first time WVE-003’s ability to selectively silence mutant HTT protein (mHTT).
Collaborations And PartnershipsWVE is eligible for up to $2.8B in total milestones and tiered royalties on net sales for these collaboration programs.
Safety ProfileThere were no severe or serious TEAEs related to study drug in the multi-dose cohort and all TEAEs were mild and moderate.
Bears Say
Clinical Study ResultsNfL levels did not show a decrease or trend in reduction in this study, but a longer-term study might be able to demonstrate an impact in the NfL levels especially if the caudate data holds true.
Market Position'N531 addresses only a fraction of patients, making the commercial outlook less clear especially against established players like SRPT.
Patient OutcomesThere is a trend of increase in NfL levels over time, with some patients showing higher-than-placebo levels, which might cap near-term upside.
---
Ownership Overview
27.79% Insiders
7.02% Mutual Funds
5.53% Other Institutional Investors
59.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
WVE FAQ
What was Wave Life Sciences’s price range in the past 12 months?
Wave Life Sciences lowest stock price was $3.50 and its highest was $7.67 in the past 12 months.
What is Wave Life Sciences’s market cap?
Currently, no data Available
When is Wave Life Sciences’s upcoming earnings report date?
Wave Life Sciences’s upcoming earnings report date is Aug 01, 2024 which is 101 days ago.
How were Wave Life Sciences’s earnings last quarter?
Wave Life Sciences released its earnings results on May 09, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.186 by -$0.054.
Is Wave Life Sciences overvalued?
According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued.
Does Wave Life Sciences pay dividends?
Wave Life Sciences does not currently pay dividends.
What is Wave Life Sciences’s EPS estimate?
Wave Life Sciences’s EPS estimate is -$0.21.
How many shares outstanding does Wave Life Sciences have?
Wave Life Sciences has 122,475,120 shares outstanding.
What happened to Wave Life Sciences’s price movement after its last earnings report?
Wave Life Sciences reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.186. Following the earnings report the stock price went down -1.538%.
Which hedge fund is a major shareholder of Wave Life Sciences?
Among the largest hedge funds holding Wave Life Sciences’s share is RA Capital Management. It holds Wave Life Sciences’s shares valued at 112M.
---
Wave Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.83 (130.88% Upside)
$13.83 (130.88% Upside)
Blogger Sentiment
Bullish
WVE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 20.4%
Last 30 Days ▲ 20.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.74%
12-Months-Change
Fundamentals
Return on Equity
-1928.16%
Trailing 12-Months
Asset Growth
-11.97%
Trailing 12-Months
Company Description
Wave Life Sciences
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
---
WVE Company Deck
---
WVE Earnings Call
Q1 2024
0:00 / 0:00
---
WVE Stock 12 Month Forecast
Average Price Target
$13.83
▲(130.88% Upside)
Technical Analysis
Best Analysts Covering WVE
1 Year
1 Year Success Rate
19/47 ratings generated profit
1 Year Average Return
-8.82%
reiterated a buy rating 5 months ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 40.43% of your transactions generating a profit, with an average return of -8.82% per trade.
---